| Disclosure of reportable segments [Table Text Block] |
| |
|
IP Development |
|
|
BioTech |
|
|
Albany Project |
|
|
Unallocated Corporate |
|
|
Total |
|
| For the years ended March 31 |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| External net sales |
|
166,048 |
|
|
79,995 |
|
|
- |
|
|
792,500 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
166,048 |
|
|
872,495 |
|
| Cost of sales |
|
1,838,971 |
|
|
578,419 |
|
|
- |
|
|
66,191 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
1,838,971 |
|
|
644,610 |
|
| Gross margin (loss) |
|
(1,672,923 |
) |
|
(498,424 |
) |
|
- |
|
|
726,309 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
(1,672,923 |
) |
|
227,885 |
|
| Depreciation and amortization |
|
526,405 |
|
|
600,322 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
526,405 |
|
|
600,322 |
|
| Interest Expense |
|
139,657 |
|
|
91,323 |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
139,657 |
|
|
91,323 |
|
| Net loss |
|
(6,742,003 |
) |
|
(7,075,798 |
) |
|
(599,857 |
) |
|
(262,462 |
) |
|
(433,253 |
) |
|
(18,597 |
) |
|
(1,992,845 |
) |
|
(2,682,801 |
) |
|
(9,767,958 |
) |
|
(10,039,658 |
) |
| Segment assets |
|
6,732,071 |
|
|
10,013,831 |
|
|
1,989 |
|
|
828,439 |
|
|
8,352,872 |
|
|
7,553,915 |
|
|
- |
|
|
- |
|
|
15,086,932 |
|
|
18,396,185 |
|
| Segment liabilities |
|
3,698,876 |
|
|
2,816,136 |
|
|
344,583 |
|
|
238,003 |
|
|
741,576 |
|
|
- |
|
|
499,753 |
|
|
592,599 |
|
|
5,284,788 |
|
|
3,646,738 |
|
| Capital expenditures |
|
2,020 |
|
|
1,398 |
|
|
- |
|
|
- |
|
|
699,842 |
|
|
183,214 |
|
|
- |
|
|
- |
|
|
701,862 |
|
|
184,612 |
|
|